Valuation: Control Bionics Limited

Market Cap 30.49M 21.29M 18.6M 17.17M 15.82M 29.82M 2.05B 205M 80.7M 1B 79.94M 78.19M 3.46B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.12M 18.46M 17.03M 15.7M 29.59M 2.03B 204M 80.07M 996M 79.32M 77.58M 3.43B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
54.68%
Yield 2024 *
-
Yield 2025 -
1 day-1.43%
1 week-1.43%
Current month-6.76%
1 month-23.33%
3 months+13.11%
6 months-2.82%
Current year+13.11%
1 week 0.06
Extreme 0.065
0.08
1 month 0.06
Extreme 0.065
0.09
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.74
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 01/12/2025
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.43%-1.43%+64.29%-18.82% 20.19M
-1.46%+4.33%+16.18%-21.89% 17.53B
-6.27%-3.41%+0.47%+82.98% 1.67B
-4.71%-4.87%-34.86%-79.09% 1.24B
-1.34%-8.52%-38.86%+8.70% 1.01B
-4.06%+5.84%-27.53%-52.68% 672M
-7.46%-0.30%-40.81%-57.56% 576M
-1.95%-4.52%+34.39%-53.87% 453M
-1.26%+1.78%-53.48%-59.43% 387M
-3.29%+16.11%+47.89% - 332M
Average -3.31%+1.09%-3.23%-27.96% 2.39B
Weighted average by Cap. -2.19%+4.09%+7.19%-19.13%

Financials

2024 2025
Net sales 5.35M 3.74M 3.27M 3.01M 2.78M 5.23M 360M 36.01M 14.16M 176M 14.03M 13.72M 607M 6.14M 4.29M 3.75M 3.46M 3.19M 6.01M 413M 41.36M 16.27M 202M 16.11M 15.76M 697M
Net income -5.91M -4.13M -3.61M -3.33M -3.07M -5.79M -398M -39.8M -15.66M -195M -15.51M -15.17M -670M -6.11M -4.27M -3.73M -3.44M -3.17M -5.98M -411M -41.11M -16.17M -201M -16.02M -15.67M -693M
Net Debt -96.95K -67.69K -59.16K -54.59K -50.32K -94.84K -6.52M -652K -257K -3.19M -254K -249K -10.99M -237K -166K -145K -134K -123K -232K -15.95M -1.6M -628K -7.81M -622K -609K -26.9M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
17/07/26 $0.0690 -1.43% 1,674,808
16/07/26 $0.0700 -5.41% 2,253,176
15/07/26 $0.0740 -1.33% 530,059
14/07/26 $0.0750 0.00% 1,035,306
13/07/26 $0.0750 +2.74% 230,680

Annual profits - Rate of surprise